Loading…
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-36M | $-42M | $-25M | -149.1% | - | - |
| 2024 | $0M | $-13M | $-17M | $-11M | -27.8% | - | -193.3% |
| 2023 | $0M | $19M | $19M | $-14M | -481.7% | - | - |
| 2022 | $0M | $-18M | $-28M | $-15M | 118.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 18.04 | 11.87 | 14.10 | 38.60 |
| Operating Income | -18.04 | -11.87 | -14.10 | -38.60 |
| EBITDA | -18.04 | 18.69 | -13.12 | -35.90 |
| EBIT | -18.04 | 18.69 | -13.12 | -35.90 |
| Pretax Income | -28.58 | 18.69 | -17.43 | -41.72 |
| Tax Provision | -1.03 | 0 | 0 | 0 |
| Net Income | -27.55 | 18.69 | -17.43 | -41.72 |
| Net Income Common Stockholders | -27.55 | 17.91 | -17.43 | -41.72 |
| Total Expenses | 18.04 | 11.87 | 14.10 | 38.60 |
| Interest Expense | 0 | 0 | 4.32 | 5.82 |
| Interest Income | 0 | 6.26 | 0.64 | 2.59 |
| Research And Development | 13.88 | 8.79 | 8.15 | 22.84 |
| Selling General And Administration | 4.16 | 3.08 | 5.94 | 15.76 |
| Normalized EBITDA | -17.74 | -4.89 | -10.51 | -35.28 |
| Normalized Income | -27.26 | -4.89 | -14.82 | -41.10 |
| Basic EPS | -2.46 | 1.60 | -7.83 | -3.71 |
| Diluted EPS | -2.46 | 1.60 | -7.83 | -3.71 |
| Tax Effect Of Unusual Items | -0.01 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.04 | 0 | 0 | 0 |
| Total Unusual Items | -0.30 | 23.58 | -2.61 | -0.61 |
| Total Unusual Items Excluding Goodwill | -0.30 | 23.58 | -2.61 | -0.61 |
| Net Income From Continuing Operation Net Minority Interest | -27.55 | 18.69 | -17.43 | -41.72 |
| Net Interest Income | -10.36 | 6.26 | -3.67 | -3.23 |
| Net Income From Continuing And Discontinued Operation | -27.55 | 18.69 | -17.43 | -41.72 |
| Total Operating Income As Reported | -18.04 | -11.87 | -14.10 | -38.60 |
| Diluted Average Shares | 11.22 | 11.22 | 2.23 | 11.25 |
| Basic Average Shares | 11.22 | 11.22 | 2.23 | 11.25 |
| Diluted NI Availto Com Stockholders | -27.55 | 17.91 | -17.43 | -41.72 |
| Preferred Stock Dividends | 0 | 0.78 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -27.55 | 18.69 | -17.43 | -41.72 |
| Net Income Continuous Operations | -27.55 | 18.69 | -17.43 | -41.72 |
| Other Income Expense | -0.17 | 24.30 | 0.34 | 0.12 |
| Other Non Operating Income Expenses | 0.13 | 0.71 | 2.95 | 0.73 |
| Special Income Charges | 0 | 23.10 | 0 | 0 |
| Other Special Charges | 0 | -23.10 | 0 | 0 |
| Gain On Sale Of Security | -0.30 | 0.48 | -2.61 | -0.61 |
| Net Non Operating Interest Income Expense | -10.36 | 6.26 | -3.67 | -3.23 |
| Total Other Finance Cost | 10.36 | -6.26 | 0 | 0 |
| Interest Expense Non Operating | 0 | 0 | 4.32 | 5.82 |
| Interest Income Non Operating | 0 | 6.26 | 0.64 | 2.59 |
| General And Administrative Expense | 4.16 | 3.08 | 5.94 | 15.76 |
| Other Gand A | 4.16 | 3.08 | 5.94 | 15.76 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Palvella Therapeutics, Inc.this co. | PVLA | $1.8B | - | 54.18 | -149.1% | - |
| Surgery Partners, Inc. | SGRY | $1.8B | - | 1.04 | -2.2% | 11.28 |
| AnaptysBio, Inc. | ANAB | $1.8B | - | 46.94 | -35.6% | 36.55 |
| Taysha Gene Therapies, Inc. | TSHA | $1.8B | - | 7.24 | -44.1% | -14.19 |
| Sonida Senior Living, Inc. | SNDA | $1.8B |
| - |
| -37500.00 |
| -125.8% |
| 57.41 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.8B | 11.23 | 2.05 | 18.2% | 4.68 |
| Recursion Pharmaceuticals, Inc. | RXRX | $1.7B | - | 1.54 | -57.0% | -1.91 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.7B | - | 5.62 | -47.4% | -9.25 |
| Nurix Therapeutics, Inc. | NRIX | $1.7B | - | 3.57 | -49.1% | -4.02 |
| Peer Median | - | 11.23 | 2.81 | -45.8% | 1.39 | |